Torbay Pharmacy Manufacturing Unit appoints md

Dr Nick Frampton to run the unit

The UK’s South Devon Healthcare NHS Foundation Trust has appointed Dr Nick Frampton as managing director of the Torbay Pharmacy Manufacturing Unit (PMU), which produces licensed pharmaceuticals, pharmaceutical specials and medical devices.

Frampton joins the firm from Advanced Medical Solutions Group, where he was vice president of sales and marketing and contributed to a period of double-digit growth. He has formerly held quality, technical and commercial roles at West Pharmaceutical Services, Ernest Jackson and Banner Pharmacaps.

You may also like

Finance

NorthEdge invests in sterile injectable CMO to accelerate international growth

Private equity firm NorthEdge has invested in sterile injectable contract manufacturer and licence holder, Torbay Pharmaceuticals (Torbay), to support its next phase of international growth
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Research & Development

Simris Biologics secures €200K funding to develop microcystin-based payloads for antibody-drug conjugates

The Berlin-based subsidiary will use the grant to advance the KlicMic R&D programme, creating targeted microcystin payloads for ADCs that aim to improve cancer therapy efficacy whilst reducing side effects
Research & Development

Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness

The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
Manufacturing

Almac expands bioavailability capabilities to address a critical need in drug development

Almac Group has completed a multimillion-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK
Finance

Fidia Farmaceutici enters the UK market with the acquisition of Altacor

Marking another significant milestone in its ongoing international expansion, the company enters the rapidly growing UK ophthalmology market, a key therapeutic area for the group
Subscribe now